weight loss drug prescriptions semaglutide tirzepatide q3 2024 data Google searches predicted surge in prescription of weight-loss drugs like Wegovy and Zepbound, study says GLP-1 prescription trends through June

Abstract Introduction Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D)

On assessing the limit of detection using the serially diluted influenza A viral isolate, application of the pipetting-based immunoassay for antigen capture with the commercial lateral flow system improved the limit of detection 100-fold more than that of the lateral flow system alone

Dietary Se-species, first of all, SeMet and selenite may substitute SELENOP deficiency

Clinical evidence: The SURMOUNT-1 trial, published in the New England Journal of Medicine , showed that participants on the highest dose of tirzepatide (15 mg) lost an average of 22.5 percent of their body weight over 72 weeks the most weight loss ever demonstrated by a pharmaceutical agent in a clinical trial (Jastreboff et al., 2022)

Glp-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art

Reduces Bone Resorption: Lowers bone turnover markers and helps preserve bone mineral density in androgen-deficient states 4